Cargando…
The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
B-cell receptors, multiple receptor tyrosine kinases, and downstream effectors are constitutively active in chronic lymphocytic leukemia (CLL) B cells. Activation of these pathways results in resistance to apoptosis and enhanced survival of the leukemic cells. Idelalisib is a highly selective inhibi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005712/ https://www.ncbi.nlm.nih.gov/pubmed/33790890 http://dx.doi.org/10.3389/fimmu.2021.608625 |
_version_ | 1783672168439087104 |
---|---|
author | Rohrbacher, Lisa Brauchle, Bettina Ogrinc Wagner, Ana von Bergwelt-Baildon, Michael Bücklein, Veit L. Subklewe, Marion |
author_facet | Rohrbacher, Lisa Brauchle, Bettina Ogrinc Wagner, Ana von Bergwelt-Baildon, Michael Bücklein, Veit L. Subklewe, Marion |
author_sort | Rohrbacher, Lisa |
collection | PubMed |
description | B-cell receptors, multiple receptor tyrosine kinases, and downstream effectors are constitutively active in chronic lymphocytic leukemia (CLL) B cells. Activation of these pathways results in resistance to apoptosis and enhanced survival of the leukemic cells. Idelalisib is a highly selective inhibitor of the PI3K p110∂ isoform and is approved for the treatment of CLL in patients with relapsed/refractory disease or in those harboring 17p deletions or tp53 mutations. Despite the initial excitement centered around high response rates in clinical trials of idelalisib, its therapeutic success has been hindered by the incidence of severe opportunistic infections. To examine the potential contribution of idelalisib to the increased risk of infection, we investigated the effects of idelalisib on the immune cell compartments of healthy donors (HDs) and CLL patients. PI3K∂ blockade by idelalisib reduced the expression levels of inhibitory checkpoint molecules in T cells isolated from both HDs and CLL patients. In addition, the presence of idelalisib in cultures significantly decreased T-cell-mediated cytotoxicity and granzyme B secretion, as well as cytokine secretion levels in both cohorts. Furthermore, idelalisib reduced the proliferation and cytotoxicity of HD NK cells. Collectively, our data demonstrate that both human T and NK cells are highly sensitive to PI3K∂ inhibition. Idelalisib interfered with the functions of T and NK cell cells from both HDs and CLL patients. Therefore, idelalisib might contribute to an increased risk of infections regardless of the underlying B-cell malignancy. |
format | Online Article Text |
id | pubmed-8005712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80057122021-03-30 The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression Rohrbacher, Lisa Brauchle, Bettina Ogrinc Wagner, Ana von Bergwelt-Baildon, Michael Bücklein, Veit L. Subklewe, Marion Front Immunol Immunology B-cell receptors, multiple receptor tyrosine kinases, and downstream effectors are constitutively active in chronic lymphocytic leukemia (CLL) B cells. Activation of these pathways results in resistance to apoptosis and enhanced survival of the leukemic cells. Idelalisib is a highly selective inhibitor of the PI3K p110∂ isoform and is approved for the treatment of CLL in patients with relapsed/refractory disease or in those harboring 17p deletions or tp53 mutations. Despite the initial excitement centered around high response rates in clinical trials of idelalisib, its therapeutic success has been hindered by the incidence of severe opportunistic infections. To examine the potential contribution of idelalisib to the increased risk of infection, we investigated the effects of idelalisib on the immune cell compartments of healthy donors (HDs) and CLL patients. PI3K∂ blockade by idelalisib reduced the expression levels of inhibitory checkpoint molecules in T cells isolated from both HDs and CLL patients. In addition, the presence of idelalisib in cultures significantly decreased T-cell-mediated cytotoxicity and granzyme B secretion, as well as cytokine secretion levels in both cohorts. Furthermore, idelalisib reduced the proliferation and cytotoxicity of HD NK cells. Collectively, our data demonstrate that both human T and NK cells are highly sensitive to PI3K∂ inhibition. Idelalisib interfered with the functions of T and NK cell cells from both HDs and CLL patients. Therefore, idelalisib might contribute to an increased risk of infections regardless of the underlying B-cell malignancy. Frontiers Media S.A. 2021-03-15 /pmc/articles/PMC8005712/ /pubmed/33790890 http://dx.doi.org/10.3389/fimmu.2021.608625 Text en Copyright © 2021 Rohrbacher, Brauchle, Ogrinc Wagner, von Bergwelt-Baildon, Bücklein and Subklewe. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Rohrbacher, Lisa Brauchle, Bettina Ogrinc Wagner, Ana von Bergwelt-Baildon, Michael Bücklein, Veit L. Subklewe, Marion The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression |
title | The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression |
title_full | The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression |
title_fullStr | The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression |
title_full_unstemmed | The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression |
title_short | The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression |
title_sort | pi3k∂-selective inhibitor idelalisib induces t- and nk-cell dysfunction independently of b-cell malignancy-associated immunosuppression |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005712/ https://www.ncbi.nlm.nih.gov/pubmed/33790890 http://dx.doi.org/10.3389/fimmu.2021.608625 |
work_keys_str_mv | AT rohrbacherlisa thepi3kselectiveinhibitoridelalisibinducestandnkcelldysfunctionindependentlyofbcellmalignancyassociatedimmunosuppression AT brauchlebettina thepi3kselectiveinhibitoridelalisibinducestandnkcelldysfunctionindependentlyofbcellmalignancyassociatedimmunosuppression AT ogrincwagnerana thepi3kselectiveinhibitoridelalisibinducestandnkcelldysfunctionindependentlyofbcellmalignancyassociatedimmunosuppression AT vonbergweltbaildonmichael thepi3kselectiveinhibitoridelalisibinducestandnkcelldysfunctionindependentlyofbcellmalignancyassociatedimmunosuppression AT buckleinveitl thepi3kselectiveinhibitoridelalisibinducestandnkcelldysfunctionindependentlyofbcellmalignancyassociatedimmunosuppression AT subklewemarion thepi3kselectiveinhibitoridelalisibinducestandnkcelldysfunctionindependentlyofbcellmalignancyassociatedimmunosuppression AT rohrbacherlisa pi3kselectiveinhibitoridelalisibinducestandnkcelldysfunctionindependentlyofbcellmalignancyassociatedimmunosuppression AT brauchlebettina pi3kselectiveinhibitoridelalisibinducestandnkcelldysfunctionindependentlyofbcellmalignancyassociatedimmunosuppression AT ogrincwagnerana pi3kselectiveinhibitoridelalisibinducestandnkcelldysfunctionindependentlyofbcellmalignancyassociatedimmunosuppression AT vonbergweltbaildonmichael pi3kselectiveinhibitoridelalisibinducestandnkcelldysfunctionindependentlyofbcellmalignancyassociatedimmunosuppression AT buckleinveitl pi3kselectiveinhibitoridelalisibinducestandnkcelldysfunctionindependentlyofbcellmalignancyassociatedimmunosuppression AT subklewemarion pi3kselectiveinhibitoridelalisibinducestandnkcelldysfunctionindependentlyofbcellmalignancyassociatedimmunosuppression |